MX360498B - Compuesto novedoso de pirimidina fusionada o sal del mismo. - Google Patents

Compuesto novedoso de pirimidina fusionada o sal del mismo.

Info

Publication number
MX360498B
MX360498B MX2016001845A MX2016001845A MX360498B MX 360498 B MX360498 B MX 360498B MX 2016001845 A MX2016001845 A MX 2016001845A MX 2016001845 A MX2016001845 A MX 2016001845A MX 360498 B MX360498 B MX 360498B
Authority
MX
Mexico
Prior art keywords
salt
pyrimidine compound
fused pyrimidine
present
novel fused
Prior art date
Application number
MX2016001845A
Other languages
English (en)
Other versions
MX2016001845A (es
Inventor
Satoru Iguchi
Takeshi Sagara
Hosoi Fumihito
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2016001845A publication Critical patent/MX2016001845A/es
Publication of MX360498B publication Critical patent/MX360498B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporciona un compuesto novedoso que tiene acción inhibidora de BTK y un efecto de supresión de la proliferación celular; también se proporciona un medicamento útil para la prevención y/o tratamiento de una enfermedad relacionada con BTK, particularmente cáncer, con base en la acción inhibidora de BTK; se describe un compuesto representado por la fórmula (I) [en donde R1 a R3, W, A, Y y Z respectivamente tienen los significados como se definió en la especificación], o una sal del mismo. (ver Fórmula).
MX2016001845A 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo. MX360498B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2016001845A MX2016001845A (es) 2016-05-16
MX360498B true MX360498B (es) 2018-11-05

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001845A MX360498B (es) 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo.

Country Status (22)

Country Link
US (1) US9580432B2 (es)
EP (1) EP2947086B1 (es)
JP (1) JP6035423B2 (es)
KR (1) KR101828187B1 (es)
CN (1) CN105452257B (es)
AU (1) AU2014307437B2 (es)
BR (1) BR112016002069B1 (es)
CA (1) CA2921208C (es)
DK (1) DK2947086T3 (es)
ES (1) ES2661733T3 (es)
HU (1) HUE036834T2 (es)
MX (1) MX360498B (es)
MY (1) MY171831A (es)
NO (1) NO2947086T3 (es)
PH (1) PH12015502737B1 (es)
PL (1) PL2947086T3 (es)
PT (1) PT2947086T (es)
RU (1) RU2666349C2 (es)
SG (1) SG11201600048VA (es)
TR (1) TR201802875T4 (es)
TW (1) TWI585089B (es)
WO (1) WO2015022926A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
CN107207517B (zh) * 2015-01-30 2019-06-07 大鹏药品工业株式会社 稠合嘧啶化合物的盐及其结晶
TR201910158T4 (tr) * 2015-01-30 2019-07-22 Taiho Pharmaceutical Co Ltd İmmün hastalıklara yönelik önleyici ve/veya terapötik ajan.
JP6141568B1 (ja) * 2015-09-01 2017-06-07 大鵬薬品工業株式会社 新規なピラゾロ[3,4−d]ピリミジン化合物又はその塩
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
CA3015484C (en) 2016-02-23 2022-11-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2018159613A1 (ja) * 2017-02-28 2018-09-07 大鵬薬品工業株式会社 ピラゾロ[3,4-d]ピリミジン化合物を用いた抗腫瘍効果増強剤
EP3674325A4 (en) 2017-08-21 2021-11-03 Taiho Pharmaceutical Co., Ltd. FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN
CA3121722C (en) * 2019-01-11 2024-01-16 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound or salt thereof
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
TWI895316B (zh) * 2019-12-19 2025-09-01 日商大鵬藥品工業股份有限公司 以縮合嘧啶化合物作為有效成分之治療劑
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4183395A4 (en) * 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2542776A1 (en) 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP5237108B2 (ja) * 2005-12-08 2013-07-17 アボット・ラボラトリーズ タンパク質キナーゼ阻害薬としての9員ヘテロ二環式化合物
US20100273776A1 (en) 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP2009235057A (ja) * 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス,インク. Bruton型チロシンキナーゼの阻害剤
JP6230530B2 (ja) * 2011-07-15 2017-11-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 薬物送達デバイス
MY171055A (en) * 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
KR20160038891A (ko) 2016-04-07
TWI585089B (zh) 2017-06-01
MX2016001845A (es) 2016-05-16
CA2921208A1 (en) 2015-02-19
HUE036834T2 (hu) 2018-08-28
PH12015502737B1 (en) 2018-08-31
US9580432B2 (en) 2017-02-28
JP6035423B2 (ja) 2016-11-30
AU2014307437B2 (en) 2016-12-15
MY171831A (en) 2019-11-01
EP2947086B1 (en) 2018-01-03
TR201802875T4 (tr) 2018-03-21
NO2947086T3 (es) 2018-06-02
CN105452257A (zh) 2016-03-30
BR112016002069B1 (pt) 2020-08-18
JPWO2015022926A1 (ja) 2017-03-02
HK1217703A1 (zh) 2017-01-20
EP2947086A4 (en) 2016-06-22
SG11201600048VA (en) 2016-03-30
PH12015502737A1 (en) 2016-03-07
CN105452257B (zh) 2017-09-05
DK2947086T3 (en) 2018-03-19
EP2947086A1 (en) 2015-11-25
BR112016002069A2 (pt) 2017-08-01
RU2666349C2 (ru) 2018-09-07
US20160115168A1 (en) 2016-04-28
RU2015156524A (ru) 2017-09-14
PT2947086T (pt) 2018-03-09
WO2015022926A1 (ja) 2015-02-19
CA2921208C (en) 2018-02-20
KR101828187B1 (ko) 2018-02-09
AU2014307437A1 (en) 2016-01-21
ES2661733T3 (es) 2018-04-03
PL2947086T3 (pl) 2018-06-29
TW201536786A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
PH12017502363A1 (en) Brk inhibitory compound
MX2015010125A (es) Derivados de piridazinona-amidas.
MX373865B (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
PH12016500225B1 (en) Novel quinoline-substituted compound
MD4666B1 (ro) Inhibitori ai Syk
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
BR112015000399A2 (pt) derivados de pirazolil pirimidina
MX2015010128A (es) Derivados de piridazinona macrociclicos.
PH12014502396B1 (en) Nitrogenated heterocyclic compound
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
MX352928B (es) Compuestos de piridazina-amida.
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EP3587400A3 (en) Process for the preparation of a pde4 inhibitor
MX349548B (es) Compuestos de tienopirimidina.
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
MX366839B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
MX2017000522A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
PH12017500492A1 (en) Crystalline bace inhibitors

Legal Events

Date Code Title Description
FG Grant or registration